导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.90% | 3876/4773 |
| 近一周 | -2.49% | 3944/5465 |
| 近一月 | -2.69% | 1824/5421 |
| 近一季 | -2.23% | 1331/5231 |
| 近半年 | -4.00% | 2683/4920 |
| 近一年 | -15.44% | 3746/4394 |
| 近两年 | 28.82% | 2333/2954 |
| 近三年 | 10.47% | 1745/2253 |
| 成立以来 | -5.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.35% 4644/4961 |
8.89% 2523/5312 |
- - |
- - |
| 2025 | 3.90% 3084/4813 |
-6.59% 3370/3635 |
4.49% 747/4076 |
11.11% 3201/4524 |
-4.19% 3414/4813 |
| 2024 | 27.04% 204/3463 |
-4.52% 1692/2808 |
-8.00% 2158/3014 |
43.20% 14/3129 |
0.99% 1140/3463 |
| 2023 | 4.44% 228/2656 |
3.99% 1076/2280 |
-3.11% 742/2385 |
8.10% 19/2515 |
-4.11% 876/2655 |
| 2022 | -23.91% 1174/2207 |
-17.63% 1231/1919 |
2.30% 1319/2016 |
-15.01% 1191/2113 |
6.24% 376/2208 |
| 2021 | 1.67% 659/1822 |
-13.16% 1154/1255 |
8.64% 610/1330 |
5.49% 269/1466 |
2.16% 671/1822 |
| 2020 | 14.38% 794/1250 |
-13.76% 938/1028 |
8.17% 831/1067 |
19.50% 69/1164 |
2.61% 979/1184 |
| 2019 | 42.21% 219/1092 |
40.99% 46/754 |
-2.41% 350/804 |
-3.92% 749/850 |
7.57% 422/918 |
| 2018 | -24.22% 320/834 |
- - |
- - |
- - |
-7.12% 56/691 |
| 2017 | 12.13% 284/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.88% 310/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时证券公司指数A VS. 长安沪深300非周期A(740101) |